Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Protea Biosciences Group Inc Common Stock (OB:PRGB)

Business Focus: N/A

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEC Form 4 filings for PRGB*US within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Oct 10, 2017 09:30 ET
Protea Announces Clinical Assay Development Plans
MORGANTOWN, W.Va., Oct. 10, 2017 /PRNewswire/ -- Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea") announced today that it plans to develop clinical screening assays in various areas of oncology.  The assays shall be developed on Bruker's rapifleX™ MALDI Tissuetyper™ using Protea's proprietary histology guided mass spectrometry workflows and expertise. 
Read full article
Aug 22, 2017 09:00 ET
Protea Expands Clinical Study for New Melanoma Test
MORGANTOWN, W.Va., Aug. 22, 2017 /PRNewswire/ -- Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea") announced today that it has expanded its clinical research study for its new molecular imaging test for the differential diagnosis of malignant melanoma. The study has now surpassed 250 patient samples.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
--
--
--
Price to Sales - TTM
--
--
--
Price to Book - most recent quarter
--
--
--
Price to Cash Flow per share - TTM
--
--
--
Price to Free Cash Flow per share - TTM
--
--
--
See all valuations

Business Summary

Sector:  N/A Industry:  N/A

See business summary

 

Twitter

Search (past week) for $PRGB

  • No tweets found